Theriva Biologics Q1 2025: VCN-01 Ph2b meets endpoints; cash runway extended into Q1 2026

Theriva Biologics, Inc.

2025-Q1 EPS reported -$1.55

VCN-01 plus gemcitabine/nab-paclitaxel increased OS, PFS, DOR in mPDAC vs SoC alone in Phase 2b.
Two doses of VCN-01 showed greater OS benefit than one dose in patients receiving ≥4 chemo cycles.
Closed public offering of 6,818,180 shares and warrants at $1.10/unit, gross proceeds ~$7.5M.
Cash balance post-offering $14.1M, extending runway into Q1 2026.
Q1 2025 G&A $1.4M (-25% YoY); R&D $3.0M (-14% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.